EditorModernaMRNACOMMENTMay 18, 2020

Down 44% in 2023. They made the first Covid vaccine and made a ton of sales, but they suffer losses now. It didn't pull off a cancer vaccine as some hoped for. But it's up 9% in the past week. Maybe there's hope.

Covid vaccine was its first commercial product, and it did well. That's trailing off. Investing in drug pipeline, and it's hard to determine when products might be approved and launched. Her preference is a more established company with a pipeline.

A good mix of consumer goods and healthcare, but the PE is extended. Prefers to buy Pfizer for its growth and lower PE. He might even roll the dice with Moderna. Or buy the IBB, biotech ETF.

Down 26% in the last 23 months. It's suffering a post-Covid hangover and the company is better than this.

Is down 22% in the last 3 months. But he would but it. They're out of fashion, sure, and it's considered a Covid name, but their science is very good. A personalized cancer vaccine is possible.

They have developed a vaccine template that will benefit them going forward. Do not sell, but add more.

In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky. 

They're holding an investor event on Monday. They delivered an early Covid vaccine, but shares have fallen since then. A smart CEO. They're working on a personalized cancer medication. 

The risk/return is elevated so be careful.

Hold it and put it away. It is event-driven. Their cancer vaccine data is coming, for instance, and will do well. This is a long-term buy.

Likes it long term. They will reveal data on a personalized cancer vaccine coming up. But short term it's volatile, anybody's guess.